Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by.

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Facial adenocarcinoma treated with intra-arterial chemotherapy

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis Lawrence F. Eichenfield, MD, Robert S. Call,

Use of Eczema Action Plans (EAPs) to improve parental understanding of treatment regimens in pediatric atopic dermatitis (AD): A randomized controlled.

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Ana Corcimaru, BS, Dean S. Morrell, MD, Craig N. Burkhart, MD

Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective β-adrenergic blocker Chia-Chi Hsu, MD,

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD

Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Amy S. Paller, MD, Elaine C. Siegfried, MD, David M

Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis I.M. Leonie Majoie,

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Reply to: “A note on normality”

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Increased serum levels of interleukin 33 in patients with atopic dermatitis Risa Tamagawa-Mineoka, MD, PhD, Yasutaro Okuzawa, MD, Koji Masuda, MD, PhD,

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Infectious rash after riding elephants

Robert Kantor, BS, Prarthana Dalal, BS, David Cella, PhD, Jonathan I

Lip edema Journal of the American Academy of Dermatology

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis Amalie.

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis.

Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study Kenji Kabashima, MD, PhD, Masutaka.

Stefan Tukaj, PhD, Detlef Zillikens, MD, Michael Kasperkiewicz, MD

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma Howard Sofen, MD,

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial Alice Gottlieb, MD, PhD, John Sullivan,

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Yu-Chen Huang, MD, Ying-Chih Cheng, MD

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Boni E. Elewski, MD, Martin.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

Alan Menter, MD, Stephen K

The epidemiology of molluscum contagiosum in children

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Reporting of harm and safety results in randomized controlled trials published in 5 dermatology journals Cynthia Haddad, PharmD, MSc, Odette Berline.

Anastasia O. Kurta, DO, Daisy Dai, PhD, Eric S

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Presentation transcript:

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE) Eric L. Simpson, MD, Carsten Flohr, MD, PhD, Lawrence F. Eichenfield, MD, Thomas Bieber, MD, PhD, MDRA, Howard Sofen, MD, Alain Taïeb, MD, Ryan Owen, PhD, Wendy Putnam, PhD, Marcela Castro, MD, Kendra DeBusk, PhD, Chin-Yu Lin, PhD, Athina Voulgari, PhD, Karl Yen, MD, Theodore A. Omachi, MD Journal of the American Academy of Dermatology Volume 78, Issue 5, Pages 863-871.e11 (May 2018) DOI: 10.1016/j.jaad.2018.01.017 Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Proportion of atopic dermatitis patients achieving (A) a 50% reduction of Eczema Area and Severity Index, (B) a 75% reduction of Eczema Area and Severity Index, (C) an Investigator Global Assessment of 0 or 1, and (D) a 50% reduction of SCORing Atopic Dermatitis at week 12 of lebrikizumab treatment. Q4W, Every 4 weeks; SD, single dose. Journal of the American Academy of Dermatology 2018 78, 863-871.e11DOI: (10.1016/j.jaad.2018.01.017) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Proportion of atopic dermatitis patients receiving lebrikizumab achieving (A) a 50% reduction of Eczema Area and Severity Index, (B) a 75% reduction of Eczema Area and Severity Index, (C) an Investigator Global Assessment of 0 or 1, and (D) a 50% reduction of SCORing Atopic Dermatitis over time. Q4W, Every 4 weeks; SD, single dose. Journal of the American Academy of Dermatology 2018 78, 863-871.e11DOI: (10.1016/j.jaad.2018.01.017) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Adjusted mean percent change from baseline in (A) pruritus Visual Analog Scale, (B) sleep loss Visual Analog Scale, (C) Atopic Dermatitis Impact Questionnaire, and (D) Dermatology Life Quality Index over time in atopic dermatitis patients receiving lebrikizumab. Q4W, Every 4 weeks; SD, single dose. Journal of the American Academy of Dermatology 2018 78, 863-871.e11DOI: (10.1016/j.jaad.2018.01.017) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Supplemental Fig 1 Atopic dermatitis patient disposition for the TREBLE study. Q4W, Every 4 weeks; SD, single dose. Journal of the American Academy of Dermatology 2018 78, 863-871.e11DOI: (10.1016/j.jaad.2018.01.017) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions